<DOC>
	<DOCNO>NCT01130909</DOCNO>
	<brief_summary>This study provide data support preclinical clinical translation align preclinical clinical efficacy assay dose dependent change EEG .</brief_summary>
	<brief_title>A Blinded , Four-Way Crossover Healthy Subjects Assess EEG After Administration Ketamine , Placebo AZD6765</brief_title>
	<detailed_description>A Phase I , Randomized , Double-Blind , Four-way Cross-over Study Healthy Subjects Assess Quantitative Electroencephalography ( qEEG ) parameter administration ketamine , two dos AZD6765 Placebo</detailed_description>
	<mesh_term>Ketamine</mesh_term>
	<criteria>BMI 1830 Nonsmoker least 4 week Any clinically relevant acute chronic disease History substance abuse Hypersensitivity ketamine</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Effect single dose gamma-band qEEG</keyword>
</DOC>